Second Department of Neurology, 'Attikon' University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Department of Neurology, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
J Hypertens. 2021 Feb 1;39(2):266-272. doi: 10.1097/HJH.0000000000002628.
To investigate the association of blood pressure BP excursions, defined as greater than 185 SBP or greater than 105 DBP, with the probability of intracranial hemorrhage (ICH) and worse functional outcomes in patients with acute ischemic stroke (AIS) treated with tissue plasminogen activator (tPA).
We performed a post hoc analysis of the CLOTBUST-ER trial. Serial BP measurements were conducted using automated cuff recording according to the recommended BP protocol guidelines for tPA administration. The outcomes were prespecified efficacy and safety endpoints of CLOTBUST-ER.
The mean number of serial BP recordings per patient was 37. Of the 674 patients, 227 (34%) had at least one BP excursion (>185/105 mmHg) during the first 24 h following tPA-bolus. The majority of BP excursions (46%) occurred within the first 75 min from tPA-bolus. Patients with at least one BP excursion in the first 24 h following tPA bolus had significantly lower rates of independent functional outcome at 90 days (31 vs. 40.1%, P = 0.028). The total number of BP excursions was associated with decreased odds of 24-h clinical recovery (OR = 0.88, 95% CI:0.80-0.96), 24-h neurological improvement (OR = 0.87, 95% CI: 0.81-0.94), 7-day functional improvement (common OR = 0.92, 95% CI: 0.87-0.97), 90-day functional improvement (common OR = 0.94, 95% CI: 0.88-0.98) and 90-day independent functional outcome (OR = 0.90, 95% CI: 0.82-0.98) in analyses adjusted for potential confounders. DBP excursions were independently associated with increased odds of any intracranial hemorrhage (OR = 1.26, 95% CI: 1.04-1.53).
BP excursions above guideline thresholds during the first 24 h following tPA administration for AIS are common and are independently associated with adverse clinical outcomes.
探讨血压波动(定义为收缩压大于 185mmHg 或舒张压大于 105mmHg)与急性缺血性脑卒中(AIS)患者接受组织型纤溶酶原激活剂(tPA)治疗后发生颅内出血(ICH)和功能结局恶化的概率之间的关系。
我们对 CLOTBUST-ER 试验进行了事后分析。根据 tPA 给药的推荐血压方案指南,使用自动袖带记录进行连续血压测量。结局是 CLOTBUST-ER 的预先指定的疗效和安全性终点。
每位患者的平均连续血压记录次数为 37 次。在 674 名患者中,227 名(34%)在接受 tPA 推注后 24 小时内至少有一次血压波动(>185/105mmHg)。大多数血压波动(46%)发生在 tPA 推注后 75 分钟内。在 tPA 推注后 24 小时内至少有一次血压波动的患者,90 天独立功能结局的发生率显著降低(31% vs. 40.1%,P=0.028)。在第一个 24 小时内的血压波动总数与 24 小时临床恢复(OR=0.88,95%CI:0.80-0.96)、24 小时神经改善(OR=0.87,95%CI:0.81-0.94)、7 天功能改善(共同 OR=0.92,95%CI:0.87-0.97)、90 天功能改善(共同 OR=0.94,95%CI:0.88-0.98)和 90 天独立功能结局(OR=0.90,95%CI:0.82-0.98)的可能性降低有关,这些分析均经过潜在混杂因素的调整。DBP 波动与任何颅内出血的可能性增加独立相关(OR=1.26,95%CI:1.04-1.53)。
AIS 患者接受 tPA 治疗后第一个 24 小时内血压超过指南阈值的波动很常见,并且与不良临床结局独立相关。